Navigation Links
Single cell amoeba increases MRSA numbers 1000- fold

Scientists in the UK have found that a type of amoeba acts as an incubator for MRSA bacteria. As amoebae are often found in healthcare environments this discovery has implications for the infection control strategies adopted by hospitals.

The single cell amoeba, Acanthamoeba polyphagam commonly eats and digests environmental bacteria. It also engulfs pathogens such as MRSA. However, instead of being digested by the amoeba, MRSA survives and replicates whilst inside the amoeba. Prof Michael Brown and colleagues at the University of Bath, found that MRSA in association with amoebae increased in numbers 1000- fold.

The pathogenic bacteria, Legionella, also replicate inside amoebae and are then released into the environment. The released bacteria are less susceptible to biocides and antimicrobials, and are more invasive than the same bacteria which have grown freely. Replication within amoebae may have the same effect on MRSA.

Amoebae, as cysts, are often dispersed by air currents, providing another means of spreading any trapped bacteria.

"We need more research into the role of amoeba in the spread of MRSA ?hospitals should aim to eradicate amoebae as well as the bacteria themselves" said Prof Brown of the Department of Pharmacy and Pharmacology, University of Bath.


'"/>

Source:Blackwell Publishing Ltd.


Page: 1

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Single stem cells from bone heal a broken heart
3. Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics
4. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes
5. Single gene is genetic switch for fly sexual behavior
6. Single microRNA causes cancer in transgenic mouse
7. Single molecular mark seen as pivotal for genome compaction in spores and sperm
8. Single molecule extends fat mice lives by reversing gene pathways associated with disease in obese
9. Genome of deadly amoeba shows surprising complexity, evidence of lateral gene transfer
10. Biologists determine genetic blueprint of social amoeba
11. MRSA use amoeba to spread, new research shows
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: